• sense clinically
  • think mechanistically
  • act interdisciplinarily
  • treat innovatively
  1. Home
  2. BSIO Faculty
  3. Prof. Dr. med. Ulrich Keller | Director Medical Department at Charité

Prof. Dr. med. Ulrich Keller

AG Ulrich Keller
Med. Klinik Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CBF)
Charité-Universitätsmedizin Berlin
Tibor-Diamantstein-Haus, Haus IB
Hindenburgdamm 30
12203 Berlin

Tel: +49 30 450 513 381
E-Mail: ulrich.keller(at)charite.de

 

Scientific Scope

Mechanism-based cancer therapies

Myc-associated cancer biology
Functional genomic screening
Aberrant Ub/SUMO activity in cancer
Chemokine receptor signaling
Functional imaging and theranostics

Group Members

Team (Charité and TUM)

  • Markus Schick, Postdoc (Charité/TUM)
  • Matthias Wirth, Dr. rer. nat., Postdoc (Charité)
  • Stefan Habringer, Dr. med., Dr. univ., Clinician scientist (Charité)
  • Jolanta Slawska, M.Sc. (TUM)
  • Konstandina Isaakidis, M.Sc. (Charité)
  • Veronika Schulze, M.Sc. (Charité)
  • Stefanos Alexandros Bamopoulos, Clinician scientist (Charité)
  • Nikita Nikita, PhD student (Charité)
  • Le Zhang, MD student (Charité)
  • Minh Ho, Technical assistant (Charité)
  • Yingfen Hong, MD student (TUM/Charité)
  • Josefina Doffo, PhD student (Charité)
  • Elena Rohleder, Dr. med., Clinician scientist (Charité)
  • Sven Liebig, Clinician scientist (Charité)
  • Francis Baumgartner, Dr. med., Clinician scientist (Charité)
  • Uta Demel, Dr. med., Clinician scientist (Charité)
  • Richard Lewis, MD student (TUM/Charité)
  • Stavroula Litsiou, Phd student (Charité/FU)
  • Laura Schmalbrock, Dr. med., Clinician scientist (Charité)

Selected References

  • Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., Schneider, L., Muckenhuber, A., Hong, Y., Siegers, G., Nilsson, L., Wirth, M., Dantes, Z., Steiger, K., Schunck, K., Langston, S., Lenhof, H.P., Coluccio, A., Orben, F., Slawska, J., Scherger, A., Saur, D., Müller, S., Rad, R., Weichert, W., Nilsson, J., Reichert, M., Schneider, G., Keller, U. (2020) "SUMO pathway inhibition targets an aggressive pancreatic cancer subtype." Gut. 2020
  • O'Connor, T., Zhou, X., Kosla, J., Adili, A., Garcia Beccaria, M., Kotsiliti, E., Pfister, D., Johlke, A.L., Sinha, A., Sankowski, R., Schick, M., Lewis, R., Dokalis, N., Seubert, B., Höchst, B., Inverso, D., Heide, D., Zhang, W., Weihrich, P., Manske, K., Wohlleber, D., Anton, M., Hoellein, A., Seleznik, G., Bremer, J., Bleul, S., Augustin, H.G., Scherer, F., Koedel, U., Weber, A., Protzer, U., Förster, R., Wirth, T., Aguzzi, A., Meissner, F., Prinz, M., Baumann, B., Höpken, U.E., Knolle, P.A., von Baumgarten, L., Keller, U., Heikenwälder, M. (2019) "Age-related Gliosis Promotes Central Nervous System Lymphoma through CCL19-mediated Tumor Cell Retention." Cancer Cell. 2019
  • Philipp-Abbrederis, K., Herrmann, K., Knop, S., Schottelius, M., Eiber, M., Lückerath, K., Pietschmann, E., Habringer, S., Gerngroß, C., Franke, K., Rudelius, M., Schirbel, A., Lapa, C., Schwamborn, K., Steidle, S., Hartmann, E., Rosenwald, A., Kropf, S., Beer, A.J., Peschel, C., Einsele, H., Buck, A.K., Schwaiger, M., Götze, K., Wester, H.J., Keller, U.(2015) "In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma." EMBO Mol Med. 2015
  • Dechow, T., Steidle, S., Götze, K.S., Rudelius, M., Behnke, K., Pechloff, K., Kratzat, S., Bullinger, L., Fend, F., Soberon, V., Mitova, N., Li, Z., Thaler, M., Bauer, J., Pietschmann, E., Albers, C., Grundler, R., Schmidt-Supprian, M., Ruland, J., Peschel, C., Duyster, J., Rose-John, S., Bassermann, F., Keller, U.(2014) "GP130 activation induces myeloma and collaborates with MYC." J Clin Invest. 2014
  • Hoellein, A., Fallahi, M., Schoeffmann, S., Steidle, S., Schaub, F.X., Rudelius, M., Laitinen, I., Nilsson, L., Goga, A., Peschel, C., Nilsson, J.A., Cleveland, J.L., Keller, U.(2014) "Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma." Blood. 2014